title: [Pregnancy in type 1 diabetes: insulin pump versus intensified conventional therapy].
abstract: OBJECTIVE
  To evaluate and compare the outcome of pregnancies in women with type 1 diabetes treated with continuous subcutaneous insulin pump or multiple insulin injections.
  
  
  METHODS
  Thirty-three patients treated with pump, 23 with multiple injections. Were mainly investigated: glycemic control (HbA1C), fetal outcome (congenital malformations, preterm delivery, perinatal mortality), rates of gestational hypertension and cesarean section.
  
  
  RESULTS
  HbA1C (1st, 2nd and 3rd trimester) with pump was not significantly different from that obtained with multiple injections (respectively, 7.5 +/- 1.24 vs 7.6 +/- 1.4; 6.34 +/- 0.6 vs 6.6 +/- 0.8; 6.6 +/- 0.7 vs 6.4 +/- 0.7). Fetal prognosis was also similar. The occurrence of gestational hypertension was linked to diabetic complications [OR 5,7, IC95% 1.24-25, p = 0.0025]. The rate of cesarean section (70% in women treated with pump) was influenced by diabetes duration. In planned pregnancy, independently of therapeutic device, HbA1C during organogenesis was better (6.9% +/- 0.78 vs 8.51 +/- 1.3, p < 0.0001) with no perinatal death and no major congenital malformation.
  
  
  CONCLUSIONS
  Fetal prognosis is not overall significantly different with insulin pump compared with intensified conventional therapy. The initiation of insulin pump therapy should not be systematic. Instead, the benefits risks ratio must be assessed resulting in a tailored prescription according to individual needs. This therapeutic choice should be discussed before conception, as planned pregnancy is a main prognostic factor. Diabetes duration and complications remain key factors for the prognosis.
authors.affiliation: Service d'endocrinologie-médecine de la reproduction, CHU de Nice, hôpital de l'Archet, route Saint-Antoine-de-Ginestière, France. hieronimus@chu-nice.fr
authors.forename: S
authors.initials: S
authors.lastname: Hiéronimus
authors.forename: C
authors.initials: C
authors.lastname: Cupelli
authors.forename: A
authors.initials: A
authors.lastname: Bongain
authors.forename: M
authors.initials: M
authors.lastname: Durand-Réville
authors.forename: F
authors.initials: F
authors.lastname: Berthier
authors.forename: P
authors.initials: P
authors.lastname: Fénichel
mesh_terms: D000328:Adult; D002585:Cesarean Section / Q000706:statistics & numerical data; D000013:Congenital Abnormalities / Q000453:epidemiology; D048909:Diabetes Complications / Q000453:epidemiology; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D046110:Hypertension, Pregnancy-Induced / Q000453:epidemiology; D007226:Infant Mortality; D007231:Infant, Newborn; D007328:Insulin / Q000008:administration & dosage*; D007332:Insulin Infusion Systems; D007752:Obstetric Labor, Premature / Q000453:epidemiology; D011247:Pregnancy; D011256:Pregnancy Outcome; D011254:Pregnancy in Diabetics / Q000188:drug therapy*; D011379:Prognosis
chemical_list: D006442:Glycated Hemoglobin; D007328:Insulin